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Abstract
What would it take in terms of the structural reforms in science, technology, and culture to cultivate sustainable
therapeutic and preventive medicine innovations against zoonotic infections such as coronavirus disease 2019
(COVID-19) in the 21st century? In May 2019, the Intergovernmental Science-Policy Platform on Biodiversity and
Ecosystem Services warned that ‘‘around one million animal and plant species are now threatened with extinc-
tion.’’ Biodiversity is essential for drug discovery and development. We are currently facing a dual challenge in
therapeutics innovation with COVID-19 and loss in planetary biodiversity. Hence, there is an urgent need for new
ideas and strategies for drug discovery as well as repurposed drugs for the COVID-19 pandemic. To these ends, the
existing scholarship in, and the field of precision herbal medicine provide an alternative source for discovery of
novel therapeutics against the novel coronavirus. We propose that the application of precision herbal medicine in
Africa could usefully contribute to current efforts for therapeutics innovation for the COVID-19 pandemic, and
beyond. The pandemic calls for interdisciplinary dialogue and turning up the volume for precision herbal medicine
in Africa, and importantly, in ways informed by robust systems science as well as broad public engagement to
codesign medicines in the 21st century.
Keywords: precision herbal medicine, COVID-19, African traditional herbal medicine, biodiversity, planetary
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Perspective
The coronavirus disease 2019 (COVID-19) pandemiccaused by the novel coronavirus, officially known as the
severe acute respiratory syndrome-coronavirus-2 (SARS-
CoV-2), has spread across the globe with 675,060 deaths
from 17,396,943 confirmed cases as of August 1, 2020, ac-
cording to the World Health Organization (WHO). There is
an urgent need for effective and safe vaccines as with novel
drug discovery strategies and repurposed therapeutics to re-
duce morbidity and mortality of COVID-19. Hence, we begin
this opinion piece with a question:
What would it take in terms of the structural reforms in
science, technology, and culture to cultivate sustainable
therapeutics innovations against zoonotic infections such as
COVID-19 in the 21st century?
To answer, let us bring forward a broader and historical
context.
First and foremost, until we examine through a critically
informed lens, the human actions on the planet for the past
centuries that have put wealth over planetary health, SARS-
CoV-2 is unlikely to be the last zoonotic outbreak in the 21st
century (Akar, 2020; Brabazon, 2020; Kickbusch et al., 2020).
To this end, it is noteworthy that in May 2019, the Inter-
governmental Science-Policy Platform on Biodiversity and
Ecosystem Services warned that ‘‘around one million animal
and plant species are now threatened with extinction’’ (Dı́az
et al., 2019). The COVID-19 pandemic signals, in part, the
effects of biodiversity loss and the blurred boundaries between
human and animal habitats that have created a fertile ground for
zoonotic infections and pandemics. In contrast, a collective
cognizance on planetary health, biodiversity loss, and design
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and implementation of strategic policies could turn the scale
toward favorable biodiversity outcomes (Bull et al., 2020).
Biodiversity is essential for drug discovery and develop-
ment particularly for antimicrobials as noted in the fungus
Penicillium chrysogenum resulting in the discovery and
isolation of penicillin in early 1940s (Newman and Cragg,
2016). Biodiversity has contributed immensely to the dis-
covery of myriad compounds produced by the variety of
species we share the planet with, including herbal plants with
a notable success. Moreover, we have to bear in mind that
COVID-19 is a zoonotic disease that jumped from animals to
humans as noted earlier. It is estimated that 60% of known
infectious diseases and *75% new or emerging infectious
diseases in people come from animals ( Jones et al., 2008;
Woolhouse and Gowtage-Sequeria, 2005). This indicates the
need for real-time, vigilant, and planetary scale therapeutics
innovation programs against zoonotic infections and new
ways to buttress and empower planetary biodiversity.
Building a Systems Science Foundation
for Precision Herbal Medicine
The pandemic has begun to spread in the global South in-
cluding Africa by February 2020 (CDC, 2020; Massinga
Loembé et al., 2020). As the scientific community continues to
search for new or repurposed drugs for COVID-19, in contrast,
there was an increased demand for herbal ‘‘COVID-Organics’’
by the Madagascar Institute of Applied Research in April 2020.
However, there was and still lack of reliable pharmacological
and efficacy data to substantiate the report that the herbal tonic
cures COVID-19. Undoubtedly, herbal medicines including
Artemisia herba-alba, Catharanthus roseus, Pelargonium
sidoides, Azadirachta indica, Moringa oleifera and many more
are used in folk medicine by many cultures. The current pan-
demic presents an opportunity for further dialogue and turning
up the volume for precision herbal medicine in Africa in ways
informed by robust systems science, omics technologies, and
glocal (global + local) practices of herbal medicine in society.
Precision herbal medicine that emphasizes the incorporation
of biomarker and systems science research with herbal medi-
cine with an eye to rational treatment algorithms can help
leverage from the large body of scholarship in personalized
medicine, molecular disease targets, and environmental factors
(including microbiota and lifestyle) that are all needed as part
of the glocal debates in finding new therapeutics and diag-
nostics solutions to the COVID-19 pandemic.
We propose that an ecological approach to drug discovery
that takes into account local community knowledge base and
one that deploys omics systems science technologies can en-
able precision herbal medicine in Africa and globally and thus
empower the current efforts for therapeutics innovation for
the COVID-19 pandemic and beyond (Sardas et al., 2020;
Thomford et al., 2018a). A systems science and multiomics
approach (Pirih and Kunej, 2018) to assess the mechanism of
action, efficacy, and safety of African herbal medicine could
help generate the much-needed robust evidence base that is
crucial in discovery of new therapeutics against the COVID-19.
African herbal medicine and its bioactive phytocompounds can
be screened against the virus with modern multiomics tech-
nologies (proteomics, transcriptomics, genomics, and meta-
bolomics) to decipher their potential molecular targets, clinical
and planetary health effects.
The extent of the clinical severity of COVID-19 is strongly
mediated by immune response that varies among infected
patients. Defined bioactive compounds modulating the im-
mune system and response offer prospects for therapeutics
innovation (Florindo et al., 2020), whereas the idea of im-
mune boosting remains contested and calls for future research
on the complex ways in which immune system interacts with
the virus and patients’ recovery from COVID-19. Deci-
phering the molecular actions of defined bioactive com-
pounds in herbal medicines with an eye to effects on the
immune pathways remains an important focus area for pre-
cision herbal medicine as exemplified by artemisinin in herb
Artemisia annua for treatment of fever, malaria, and respi-
ratory tract infections in Africa and other continents (Cheong
et al., 2020).
African countries have a long history of and engagement
with African traditional herbal medicine that presents a dual
opportunity for therapeutics innovation and buttressing eco-
system health especially considering the threats to planetary
scale loss of biodiversity that was used to sustain novel drug
discovery in the past.
Translational multiomics-based sciences and systems
pharmacology offer a platform for identification of com-
pounds through multilayered and interactive biological net-
works, biomarkers, and targets for innovative therapeutics
for COVID-19 (Özdemir, 2015; Thomford et al., 2018b).
COVID-19 being a multisystemic disease will also require
novel therapeutic compounds to combat the disease over and
beyond the current pandemic. Preclinical and clinical trials of
mechanistically defined herbal medicines and other plant-
based drugs, for example, artesunate that are currently known
and used in African countries to have immunomodulatory
and antiviral properties are urgently required to be under-
taken as part of the precision medicine research that is nec-
essary for COVID-19.
Similar efforts for therapeutics innovation using traditional
and herbal medicines have been made against the complex
and diverse clinical findings of COVID-19 around the world,
including in China (Xiong et al., 2020; Xu and Zhang, 2020).
Such efforts to bridge traditional therapeutics folklore in
local communities would benefit from deploying systems
science concepts and multiomics technologies so as to build a
strong evidence base and independent replication of the
findings essential for progress in global science.
It should be clear by now that addressing the COVID-19
pandemic is only a first step in the arduous and long-haul task
of pandemics in the 21st century. While facing a serious
biodiversity loss, we can harness a twin success by enhancing
biodiversity on the planet and a deeper scientific under-
standing of the mechanism of action and clinical pharma-
cology of herbal medicines. Protecting and effective
utilization of herbal medicine biodiversity (Yacoub et al.,
2014) will be key to combating future diseases and pan-
demics. Nature in this regard cannot be continuously dis-
missed as it has always come to the rescue of humankind
when it needed it most (Neergheen-Bhujun et al., 2017).
The success of precision herbal medicine in the COVID-
19 era calls for an ‘‘all hands-on deck’’ approach and the
collective efforts of the African scientists, local communi-
ties, health care workers, critical social sciences, and hu-
manities scholars as well as governments. African countries
have built a strong foundation in theory and practice of














































systems science over the past several decades and are well
poised to deliver on the scientific potentials of precision
herbal medicine in a time of COVID-19 and threats to
biodiversity in the current century.
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Özdemir V. (2015). OMICS 2.0: An accelerator for global sci-
ence, systems medicine and responsible innovation. OMICS
19, 579–580.
Pirih N, and Kunej T. (2018). An updated taxonomy and a
graphical summary tool for optimal classification and com-
prehension of omics research. OMICS 22, 337–353.
Sardas S, Buyuk AS, and Beceren A. (2020). It is time to re-
vitalize the antibiotic pipeline: Systems ecology can help.
OMICS 24, 124–128.
Thomford NE, Dzobo K, Chimusa E, et al. (2018a). Persona-
lized herbal medicine? A roadmap for convergence of herbal
and precision medicine biomarker innovations. OMICS 22,
375–391.
Thomford NE, Senthebane DA, Rowe A, et al. (2018b). Natural
products for drug discovery in the 21st century: Innovations
for novel drug discovery. Int J Mol Sci 19, 1578.
Woolhouse ME, and Gowtage-Sequeria S. (2005). Host range
and emerging and reemerging pathogens. Emerg Infect Dis
11, 1842–1847.
Xiong X, Wang P, Su K, Cho WC, and Xing Y. (2020). Chinese
herbal medicine for coronavirus disease 2019: A systematic
review and meta-analysis. Pharmacol Res 160, 105056.
Xu J, and Zhang Y. (2020). Traditional Chinese Medicine
treatment of COVID-19. Complement Ther Clin Pract 39,
101165.
Yacoub K, Cibis K, and Risch C. (2014). Chapter 1: Biodi-
versity of Medicinal Plants: Biodiversity of Natural Products
and Cancer Treatment (World Scientific, Munich). pp. 1–32.
Address correspondence to:
Nicholas Ekow Thomford, PhD
Division of Human Genetics
Department of Pathology and Institute for Infectious
Disease and Molecular Medicine
Faculty of Health Sciences






COVID-19 ¼ coronavirus disease 2019
SARS-CoV-2 ¼ severe acute respiratory
syndrome-coronavirus-2
WHO ¼ World Health Organization
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